<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>MDS/AML in randomized ovarian cancer PARP inhibitor maintenance trials</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">MDS/AML in randomized ovarian cancer PARP inhibitor maintenance trials</h1>
<div class="graphic"><div class="figure"><div class="ttl">MDS/AML in randomized ovarian cancer PARP inhibitor maintenance trials</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Trial</td> <td class="subtitle1" rowspan="2">Agent</td> <td class="subtitle1" rowspan="2">PARPi duration</td> <td class="subtitle1" colspan="2">MDS/AML events by arm/total # of patients</td> <td class="subtitle1" rowspan="2">% patients with MDS/AML in PARPi versus comparator arm</td> </tr> <tr> <td class="subtitle2">PARPi</td> <td class="subtitle2">Comparator</td> </tr> <tr> <td class="subtitle3_left_align" colspan="6"><strong>After completion of first-line therapy</strong></td> </tr> <tr> <td class="indent1">SOLO1<sup>[1]</sup></td> <td>Olaparib</td> <td>2 years</td> <td>3/260</td> <td>0/130</td> <td>1.2 versus 0</td> </tr> <tr> <td class="indent1">PRIMA<sup>[2]</sup></td> <td>Niraparib</td> <td>3 years</td> <td>1/484</td> <td>0/244</td> <td>&lt;1 versus 0</td> </tr> <tr> <td class="indent1">PAOLA1<sup>[3]</sup></td> <td>Olaparib</td> <td>2 years</td> <td>6/535</td> <td>1/267</td> <td>1 versus &lt;1</td> </tr> <tr> <td class="subtitle3_left_align" colspan="6"><strong>After completion of second-line or greater platinum-sensitive chemotherapy</strong></td> </tr> <tr> <td class="indent1">Study19<sup>[4]</sup></td> <td>Olaparib</td> <td>Until disease progression, 18% &gt;3 years</td> <td>2/136</td> <td>1/129</td> <td>1.5 versus &lt;1</td> </tr> <tr> <td class="indent1">SOLO2<sup>[5]</sup></td> <td>Olaparib</td> <td>Until disease progression, mean 29.1 months</td> <td>16/195</td> <td>4/99</td> <td>8 versus 4</td> </tr> <tr> <td class="indent1">NOVA<sup>[6]</sup></td> <td>Niraparib</td> <td>Until disease progression</td> <td>13/367</td> <td>3/179</td> <td>3.5 versus 1.7</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>g<em>BRCA</em>m</li> </ul> </td> <td> </td> <td> </td> <td>9/136</td> <td>6/56</td> <td>6.6 versus 3.1</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>non-g<em>BRCA</em>m</li> </ul> </td> <td> </td> <td> </td> <td>4/231</td> <td>1/114</td> <td>1.7 versus 0.9</td> </tr> <tr> <td class="indent1">ARIEL3<sup>[7]</sup></td> <td>Rucaparib</td> <td>Until disease progression, median 8.3 months</td> <td>3/375</td> <td>0/189</td> <td>1 versus 0</td> </tr> </tbody></table></div><div class="graphic_lgnd">Median time to onset of MDS/AML 17.8 months.<sup>[8]</sup></div><div class="graphic_footnotes">MDS: myelodysplastic syndrome; AML: acute myeloid leukemia; PARP: poly(ADP-ribose) polymerase; PARPi: PARP inhibitor; g<em>BRCA</em>m: mutations in breast cancer susceptibility genes 1 and 2.</div><div class="graphic_reference">References: 

<ol>
<li>Bradley W, Moore K, Colombo N, et al. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1. Gynecol Oncol 2021; 162S; SGO #38.</li>
<li>Gonzalez-Martin A, Pothouri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019; 381:2391.</li>
<li>Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019; 381:2416.</li>
<li>Ledermann J, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet 2016; 17:1579.</li>
<li>Poveda A, Floquet A, Ledermann JA, et al. Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. J Clin Oncol 2020; 38S: ASCO #6002.</li>
<li>Matulonis U, Herrstedt J, Oza A, et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. Gynecol Oncol 2021; 162S; SGO #37.</li>
<li>Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390:1949.</li>
<li>Morice PM, Leary A, Dolladille, C, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: A safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol 2021; 8:e122.</li></ol></div><div id="graphicVersion">Graphic 132452 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
